or Try an Advanced Search...

    Technical Analysis for OKYO - OKYO Pharma Limited

    Grade Last Price % Change Price Change
    C 1.03 -3.60% -0.04
    OKYO closed up 3.88 percent on Wednesday, November 20, 2024, on 85 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical OKYO trend table...
    Date Alert Name Type % Chg
    Crossed Above 50 DMA Bullish -3.60%
    Stochastic Buy Signal Bullish -3.60%
    Pocket Pivot Bullish Swing Setup -3.60%
    Gapped Up Strength -3.60%
    Oversold Stochastic Weakness -3.60%
    Pocket Pivot Bullish Swing Setup 0.15%
    NR7 Range Contraction 0.15%
    Gapped Up Strength 0.15%
    Oversold Stochastic Weakness 0.15%
    MACD Bearish Centerline Cross Bearish 1.13%
    Older End-of-Day Signals for OKYO ...

       Recent Intraday Alerts

    Alert Time
    60 Minute Opening Range Breakdown about 1 hour ago
    Down 3% about 1 hour ago
    Fell Below 50 DMA about 1 hour ago
    Down 2 % about 1 hour ago
    Down 1% about 1 hour ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    OKYO Chart by TradingView
    Basic chart:

    Profile

    OKYO Pharma Limited (Nasdaq: OKYO, LSE: OKYO) is a biotechnology company developing next-generation therapeutics to improve the lives of patients suffering from inflammatory eye diseases and ocular pain. OKYO’s research program is focused on a novel G Protein-Coupled Receptor, or GPCR, which OKYO believes plays a key role in the pathology of these inflammatory eye diseases of high unmet medical need. OKYO’s therapeutic approach is focused on targeting inflammatory and pain modulation pathways that drive these conditions. The Company is presently developing OK-101, its lead preclinical product candidate, for the treatment of dry-eye disease “DED”. The Company also plans to evaluate its potential in benefiting patients with ocular neuropathic pain, uveitis and allergic conjunctivitis.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Clinical Medicine Immunology Pain Eye Diseases Inflammatory Uveitis Allergic Conjunctivitis Dry Eye Disease Conjunctivitis Measles Treatment Of Dry Eye Disease

    Is OKYO a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 3 bullish, 1 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 15 MUSQ Global Music Industry ETF and OKYO Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
    Oct 30 OKYO Pharma to Present at International Tear Film and Ocular Surface Society Conference
    Oct 23 OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain
    Oct 16 OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain
    Aug 26 Why MIRA Pharmaceuticals Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket
    Aug 23 OKYO Pharma CEO Interview to Air on Bloomberg TV
    Aug 23 OKYO Pharma and SolarMax Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
    Aug 23 OKYO Pharma Announces Chairman Acquires Shares
    Aug 15 OKYO Pharma Participates in H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
    Jul 11 OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101
    See more OKYO news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 2.12
    52 Week Low 0.8075
    Average Volume 65,159
    200-Day Moving Average 1.27
    50-Day Moving Average 1.06
    20-Day Moving Average 1.12
    10-Day Moving Average 1.08
    Average True Range 0.08
    RSI (14) 48.19
    ADX 25.85
    +DI 20.61
    -DI 15.59
    Chandelier Exit (Long, 3 ATRs) 1.11
    Chandelier Exit (Short, 3 ATRs) 1.21
    Upper Bollinger Bands 1.23
    Lower Bollinger Band 1.00
    Percent B (%b) 0.29
    BandWidth 20.29
    MACD Line -0.01
    MACD Signal Line 0.00
    MACD Histogram -0.0126
    Fundamentals Value
    Market Cap 35.56 Million
    Num Shares 33.2 Million
    EPS -0.61
    Price-to-Earnings (P/E) Ratio -1.75
    Price-to-Sales 0.00
    Price-to-Book 14.11
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.19
    Resistance 3 (R3) 1.19 1.14 1.17
    Resistance 2 (R2) 1.14 1.11 1.14 1.16
    Resistance 1 (R1) 1.11 1.09 1.12 1.11 1.16
    Pivot Point 1.06 1.06 1.07 1.06 1.06
    Support 1 (S1) 1.03 1.03 1.05 1.03 0.98
    Support 2 (S2) 0.98 1.01 0.99 0.98
    Support 3 (S3) 0.95 0.98 0.97
    Support 4 (S4) 0.95